Drug-Eluting Vascular Stent System · 180 Patients RANGER ALL-COMERS REGISTRY RangeR DCB...
2
choice I want I want the most clinically-proven therapies for my SFA patients Only Boston Scientific offers me the full range of clinically-proven therapeutic tools to treat SFA, from the ELUVIA ™ Drug-Eluting Vascular Stent System to the Ranger ™ Paclitaxel-Coated PTA Balloon Catheters. RANGER TM Paclitaxel-Coated PTA Balloon Catheter ELUVIA TM Drug-Eluting Vascular Stent System www.bostonscientific.eu © 2017 Boston Scientific Corporation or its affiliates. All rights reserved. DINPER4707EB Ranger™ Paclitaxel-Coated PTA Balloon Catheter is manufactured by Hemoteq AG and distributed by Boston Scientific Corporation. Eluvia is a registered or unregistered trademark of Boston Scientific Corporation or its affiliates. All cited trademarks are the property of their respective owners. InPact™ is a registered trademark of Medtronic. Zilver™ PTX is a registered trademark of Cook Medical. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. Material not intended for use in France. PI-465801-AB-APR2017 Printed in Germany by medicalvision. 2 Platforms 20 Global Trials 3 500 Patients INVESTING GLOBALLY IN PERIPHERAL DRUG-ELUTING TECHNOLOGIES
Transcript of Drug-Eluting Vascular Stent System · 180 Patients RANGER ALL-COMERS REGISTRY RangeR DCB...
choiceI want
I want the most clinically-proven therapies for my SFA patientsOnly Boston Scientific offers me the full range of clinically-proven therapeutic tools
to treat SFA, from the ELUVIA™ Drug-Eluting Vascular Stent System to the Ranger™
Paclitaxel-Coated PTA Balloon Catheters.
RANGERTM
Paclitaxel-Coated PTA Balloon Catheter
ELUVIATM
Drug-Eluting Vascular Stent System
www.bostonscientific.eu
© 2017 Boston Scientific Corporationor its affiliates. All rights reserved.DINPER4707EB
Ranger™ Paclitaxel-Coated PTA Balloon Catheter is manufactured by Hemoteq AG and distributed by Boston Scientific Corporation. Eluvia is a registered or unregistered trademark of Boston Scientific Corporation or its affiliates.All cited trademarks are the property of their respective owners. InPact™ is a registered trademark of Medtronic. Zilver™ PTX is a registered trademark of Cook Medical. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. Material not intended for use in France.
PI-465801-AB-APR2017 Printed in Germany by medicalvision.
2 Platforms
20 Global Trials
3 500 Patients
INVESTING GLOBALLY IN PERIPHERAL DRUG-ELUTING TECHNOLOGIES
180 Patients
RANGER ALL-COMERS
REGISTRY RangeR DCB
All-comers, prospective, multicentre registry
150 Patients, extension to 414 patients
COMPARE I RangeR DCB
Prospective, multicentre, 1:1 randomisation RANGER vs. IN.PACT™ DCB
200 Patients
222 Patients
250 Patients
HAEMODIALYSIS AVF RESCUE RangeR DCB
Prospective, multicentre, 1:1 randomisation
BTK ANGIOGRAPHIC
RangeR DCB
30 Patients
70 Patients
Feasibility, observational, angiography follow-up
BTK CLINICAL RangeR DCB
Prospective, 1:1 randomisation vs. PTA
Investigator Sponsored Research
SPORTS
JET-PCB (IDE)
Prospective, multicentre, RCT 1:1:1 (DES:DCB:BMS)
Prospective, multicentre, RCT 2:1 (JETSTREAM + Ranger : PTA + Ranger)
Currently enrolling123 Patients China
Prospective, multicentre, single-arm, open label
australia, new Zealand, europe 2-Year Data available
Prospective, multicentre, 2:1 randomisation vs. Zilver PTX™
enrolment completed
Currently enrolling
Prospective, multicentre, 2:1 randomisation vs. BMS
750 Patients
500 Patients Currently enrolling
All-comers, prospective, multicentre registry
376 Patients
europe, USa, new Zealand, Japan, Canada
europe, USa, new Zealand, Japan, Canada
2017 First Patient In
2017 First Patient In
2017 First Patient In
Interim Data available
Currently enrolling
Currently enrolling
Currently enrolling
enrolment completed for phase 1
Prospective, multicentre, randomisation 3:1
105 Patients 1-Year Data available
Prospective, multicentre, randomisation vs. PTA
Prospective, multicentre, single-arm, open label
Ranger DCB
Eluvia DES
MaJeSTIC
IMPeRIaL RCT
eMInenT RCT
RegaL RegISTRY
RangeR II
RangeR SFa
RangeR SFa / PPa ChIna
57 Patients
485 Patients
europe
europe
europe
USa
Sweden
France
United Kingdom
germany, austria
germany, Switzerland
europe
RCT Randomized Controlled TrialDCB Drug-Coated BalloonDeS Drug-eluting StentBMS Bare Metal StentPTa Percutaneous Transluminal angioplasty SFa Superficial Femoral arteryPCB Paclitaxel-Coated Balloon
